Welcome to our dedicated page for Vor Biopharma news (Ticker: VOR), a resource for investors and traders seeking the latest updates and insights on Vor Biopharma stock.
Vor Biopharma Inc (VOR) is a clinical-stage biotechnology pioneer developing engineered hematopoietic stem cell (eHSC) therapies for hematological cancers. This page serves as the definitive source for verified corporate announcements, clinical trial updates, and strategic developments related to their innovative platform.
Investors and researchers will find timely updates on key milestones including trial progress, regulatory filings, and partnership announcements. All content is curated to provide actionable insights into the company’s novel approach to protecting healthy cells during cancer treatments while enabling targeted tumor eradication.
The resource features press releases covering financial results, manufacturing advancements, and peer-reviewed research publications. Scientific updates detail progress in their eHSC platform’s applications for CAR-T therapies and antigen-targeted treatment regimens.
Bookmark this page for streamlined access to Vor Biopharma’s latest developments in cell engineering and hematological oncology research. Regularly updated to reflect new data presentations, clinical collaborations, and pipeline expansions.
RemeGen (REGMY) announced that its 48-week open-label extension data from the China Phase III clinical study of telitacicept for generalized myasthenia gravis (gMG) has been selected for oral presentation at the 2025 AANEM Annual Meeting on October 29, 2025.
The previously presented 24-week data showed exceptional results with 98.1% of patients achieving ≥3 points improvement in MG-ADL score and 87% achieving ≥5 points improvement in QMG score, demonstrating the highest MG-ADL response rate among Phase III gMG treatments. In June 2025, RemeGen out-licensed telitacicept to Vor Bio (VOR), which is now conducting global Phase III trials across multiple regions.
Vor Bio (NASDAQ:VOR) announced that 48-week clinical data from their Phase 3 study of telitacicept in adults with generalized myasthenia gravis will be presented at the upcoming American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting. The study, conducted in China and sponsored by Vor's collaborator RemeGen, will be featured as an oral presentation on October 29, 2025, at 10:50am PT at the Hilton San Francisco Union Square.
The presentation will focus on the efficacy and safety results of telitacicept in patients with generalized myasthenia gravis, as part of the Myasthenia Gravis Foundation of America session.
Vor Bio (NASDAQ:VOR), a clinical-stage biotech company focused on autoimmune disease treatments, has announced its participation in the upcoming Stifel 2025 Virtual Immunology and Inflammation Forum. The company will engage in a fireside chat on Monday, September 15, 2025, from 4:00-4:25 pm ET in Track 1.
The virtual event will also include one-on-one meetings with investors. Both live webcast and replay of the fireside chat will be accessible through Vor Bio's investor relations website.
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune diseases, has appointed Dr. Adi Osovsky as General Counsel. Dr. Osovsky brings 17 years of experience in biotechnology and pharmaceutical legal counsel.
Dr. Osovsky joins from iTeos Therapeutics, where she served as Executive Vice President, Head of Legal & Corporate Secretary. She previously held senior legal roles at Sarepta Therapeutics and was an associate at Sullivan & Worcester LLP. She holds an LL.B. from Tel Aviv University and both an LL.M. and S.J.D. in Securities Regulation from Harvard Law School.
PureTech Health (NASDAQ/LSE: PRTC) released its H1 2025 results, highlighting strong financial position with $319.6M in PureTech-level cash and operational runway into 2028. The company announced strategic refinements to its hub-and-spoke biotherapeutics model, focusing on capital-efficient development of high-potential programs.
Key developments include the launch of Celea Therapeutics to advance deupirfenidone, with Phase 3 trial initiation planned for H1 2026, and continued progress in Gallop Oncology's Phase 1b trial. The company maintains significant interests in various Founded Entities and retains rights to milestone payments and royalties from Karuna's Cobenfy™ following its acquisition by Bristol Myers Squibb.
Under new interim leadership with Sharon Barber-Lui as Board Chair and Robert Lyne as CEO, PureTech is strengthening its UK market presence and plans to add two new directors with UK capital markets expertise.
Vor Bio (Nasdaq: VOR) announced that its collaborator RemeGen achieved the primary endpoint in Stage A of a Phase 3 clinical study for telitacicept in treating IgA nephropathy (IgAN). The multicenter, randomized, double-blind, placebo-controlled trial enrolled 318 adult IgAN patients and demonstrated a significant 55% reduction in 24-hour urine protein-to-creatinine ratio (UPCR) at 39 weeks compared to placebo (p<0.0001).
The drug showed a favorable safety profile and demonstrated consistent disease-modifying activity across multiple autoimmune conditions. RemeGen plans to submit a Biologics License Application (BLA) to Chinese regulators, which if approved, would mark telitacicept's fifth approved indication in China.
Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company focused on autoimmune disease treatments, has announced its participation in two upcoming investor conferences. The company will participate in a fireside chat at Citi's 2025 Biopharma Back to School Conference on September 2nd, 2025, at 11:15am ET in Boston. Additionally, Vor Bio will hold one-on-one investor meetings at the Baird 2025 Global Healthcare Conference on September 9th, 2025, in New York.
A live webcast of the Citi conference fireside chat will be accessible through the company's investor relations website at www.vorbio.com, where an archived replay will also be available.
Vor Bio (Nasdaq: VOR), a clinical-stage biotech company, announced inducement grants to seven new employees between August 4-18, 2025. The grants include 6,959,013 stock options and 1,491,217 restricted stock units (RSUs).
The stock options have exercise prices of $2.04-$2.11 per share with a ten-year term. Both options and RSUs follow a four-year vesting schedule, with 25% vesting after 12 months, followed by monthly vesting for options and quarterly vesting for RSUs over the next 36 months. These grants were made under the Vor Biopharma Inc. 2023 Inducement Plan in compliance with Nasdaq Listing Rule 5635(c)(4).
Vor Bio (Nasdaq: VOR) announced that its collaborator RemeGen achieved the primary endpoint in a Phase 3 clinical study for telitacicept in treating primary Sjögren's disease. The study demonstrated that telitacicept significantly improved disease activity as measured by ESSDAI (EULAR Sjögren's syndrome disease activity index) compared to placebo, while maintaining a favorable safety profile.
RemeGen plans to submit a Biologics License Application (BLA) to Chinese regulators, which would make this telitacicept's fourth approved indication in China. The dual BAFF/APRIL inhibitor targets both upstream and downstream autoimmune signaling, potentially offering disease-modifying benefits rather than just symptom management.
Vor Bio (Nasdaq: VOR) has appointed Dallan Murray as Chief Commercial Officer, effective immediately. Murray brings over 25 years of experience in commercial strategy and global product launches from companies including Sarepta Therapeutics, where he achieved $1.8 billion in net product revenue in 2024.
Murray's extensive experience includes successful launches at major biotech companies, notably INCIVEK at Vertex Pharmaceuticals (fastest biotech launch to reach $1 billion), and strategic roles at Gilead Sciences, Biogen, and Johnson & Johnson. At Vor Bio, he will focus on commercialization strategy for telitacicept, which is currently approved in China for multiple autoimmune indications and advancing through global Phase 3 development.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
